Plain-English translation of NCT04747236 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether plus —a combination of two medications—can help people with peripheral T-cell lymphoma (PTCL) whose cancer has come back or stopped responding to prior treatment. PTCL is a rare and aggressive type of blood cancer that often resists standard chemotherapy. Half of participants will receive the new two-drug combination, while the other half will receive one of several standard single-drug treatments chosen by their doctor, so researchers can compare which approach works better.
PTCL is a very aggressive cancer that often doesn't respond well to conventional chemotherapy, leaving patients with limited options when their cancer returns or worsens. This trial exists to see whether combining these two medications might give people better outcomes and longer periods without cancer progression compared to the standard treatments currently available.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the two-drug combination or one of the standard single-drug treatments. If you receive the new combination, you will take a daily oral medication for two weeks of each 35-day cycle and receive an intravenous infusion three times per cycle. You will have regular clinic visits for blood work, imaging scans, and check-ins to monitor how you're responding and to watch for any side effects. The trial involves about 50 participants total across multiple medical centers.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States